R espiratory diseases affect millions of Canadians, with prevalence rates projected to climb. It is expected that the number of individuals living with chronic obstructive pulmonary disease (COPD) in Canada will increase from one million in 2012 to an estimated 3.5 million in 2042 (1) . Similarly, the prevalence of asthma in Canada is expected to increase from 4.4 million in 2012 to 5.9 million in 2024 (1) . Respiratory diseases are the third most common reason for hospitalization and death (1) , and have a significant economic impact on the Canadian health care system. In 2007, accounting for more than 6.0% of total health care costs, nearly $5.70 billion in direct costs and $6.72 billion in indirect costs were associated with respiratory disease (2) . Therefore, there is significant need for accelerated novel medicine development for respiratory diseases in Canada.
Innovative medicines have the potential to improve patients' quality of life, reduce the morbidity associated with respiratory disease, prolong patients' lives and, as such, reduce the burden of disease on the health care system. The development of innovative medicines is long and inherently risky due to the high failure rate of drug development: for every 5000 to 10,000 compounds screened for the required biological activity, 250 enter into preclinical testing, of which only five are ever tested in humans (3) . Clinical research is the most expensive phase of drug development and consumes the majority of industry's research and development (Rx&D) investment.
Clinical research facilitates patients' access to innovative medicines, improves health outcomes and increases knowledge acquisition by clinicians. Furthermore, the contribution of the innovative life sciences industry and its clinical trial research has a major impact on the local economy and health care system. The clinical trial research activities in respiratory disease also provide unique training opportunities and increase the global influence of Canadian respirologists.
As such, the clinical research landscape has become highly competitive in recent years (4) . Much of the early stage clinical researchapproximately 62% of the international active trials in phase I and 42% of phase II active trials -is performed in the United States. In contrast, the majority of the active trials in phase III and IV (37% and 38%, respectively) are being conducted in Western Europe (4) .
There are currently >3000 ongoing clinical trials in Canada, accounting for 5% to 7% (depending on the phase of development) of international active clinical trials. These clinical trials, however, have not been divided into therapy areas or diseases. Due to this paucity of information, it is difficult to evaluate the numbers and trends of clinical research associated with respiratory disease in Canada. As a Clinical research bridges patients' unmet medical need with innovative medicines, increases knowledge acquisition by clinicians, and creates solutions to improve the sustainability and quality of the Canadian health care system and economy. The Canadian Institutes of Health Research and the Canadian Lung Association have recently raised concerns over declining research activities within the Canadian respiratory community. While there are currently >3000 ongoing clinical trials in Canada, the number of trials investigating common respiratory diseases is unknown. The objective of the present study was to monitor the trends in industry-and nonindustry-sponsored respiratory clinical trials in Canada from 2001 to 2011. Trialtrove 2012 (Citeline, an Informa UK business), a database containing summarized clinical trial information regarding pharmaceutical products, was searched using common chronic respiratory disease terms: "allergic rhinitis", "asthma", "chronic obstructive pulmonary disease (COPD)", "cystic fibrosis", "respiratory infections", "pulmonary fibrosis" and "smoking cessation". Over the past 10 years, the number of respiratory clinical trials conducted in Canada has increased (4.49 per year; P=0.004). From 2001 to 2011, the majority of trials were performed in asthma, followed closely by respiratory infections and COPD. Over the past decade, the number of trials investigating COPD and respiratory infections increased (P<0.05), while asthma trials showed a declining trend since 2007. Of the clinical trials performed during this 10-year period, the majority were in phase III, with a significant increase in the number of phase II trials (2.49 per year; P=0.008). However, certain trends observed are concerning and warrant further monitoring in the coming years. 
METHODS
Trialtrove 2012 (Citeline, an Informa UK business), a database containing summarized clinical trial information, was searched for trials conducted in Canada between 2001 and 2011 in the following disease types: allergic rhinitis, asthma, COPD, cystic fibrosis, respiratory infections, pulmonary fibrosis and smoking cessation. The Trialtrove dataset only includes trials investigating a marketed or developmental drug and does not include observational studies. Trialtrove was chosen because it had a large number of clinical trials in the database for most disease categories. Furthermore, the sources used by Trialtrove to populate the database are varied and include, but are not limited to, web sources (ClinicalTrials.gov, Cancer.gov, controlled trials UK, Centerwatch), company conference calls with analysts, securities and exchange commission filings, news feeds, press releases and medical meetings (5) . Each trial is categorized based on disease type and disease type assignment is based on Trialtrove's 'Disease Scope Statement' for that disease.
Only trials designated as 'Open enrollment' (subject recruitment stage), 'Closed enrollment' (subject enrollment is complete, but trial is still ongoing), 'Completed enrollment' (trial is completed and primary endpoints have been reported) and 'Temporarily closed' (subject recruitment or enrollment has been suspended but may resume) were included in the search. Disease type was kept consistent with the category assigned in Trialtrove, but duplicate studies with the same protocol title, sponsor, phase and indication were removed. The designated therapy area in these cases was chosen from assessment of the primary objective of the trial. Only one study, including both asthmatic and COPD subjects, was included in both the 'asthma' and the 'COPD' therapy area and, as such, was counted twice. Studies only designated to be within the respiratory therapy area due to trial outcomes involving multiple organ systems were excluded. The dataset included industryand non-industry-sponsored trials.
Trial phases were defined by Trialtrove as follows: Phase I -generally studies conducted in a small number of healthy volunteers, these studies are conducted to determine a drug's safety profile as well as its pharmacokinetic and/or pharmacodynamic profile; Phase I/IIdescribes trials that are combination of phase I and II; Phase II -typically dose-ranging studies including a larger group of subjects that have the disease, disorder or addiction of interest. These trials evaluate safety and efficacy of the drug at a range of doses; Phase II/IIIdescribes trials that are combination of phases II and III; Phase IIItypically confirm the safety and efficacy of a drug at selected doses in a large group of patients. These studies may also compare the drug against the current 'gold standard' of treatment; Phase III/IVdescribes trials that are a combination of phases III and IV; Phase IV -are typically conducted after a drug is approved and marketed and evaluate the safety and effectiveness of the drug in large numbers of patients or in subpopulations. In the present article, the trials reported by Trialtrove as phase I/II were included with phase II trials, those reported as phase II/III were included with phase III trials and those reported as phase III/IV were included with phase IV trials.
The total number of respiratory trials were reported in whole numbers and summarized graphically. Several grouping variables, such as disease types, trial phase and trial sponsor type, were used to determine the number of trials with the specific categorization. To estimate the trend in the total number of trials conducted during the study period, linear regression was used to fit the number of trials to a linear model to determine the average annual growth in the number of trials. Additionally, linear regression was performed to determine the trial trends in each specific disease type, trial phase and trial sponsor type. The trends in the number of trials were described by change in number of trials per one year over the 10-year study period (Table 1) , with its associated P value, with a null hypothesis of no change in the number of trials per year over the 10-year period. All statistical analyses were performed using Excel 2007 (Microsoft Corporation, USA).
RESULTS
Over the 10-year period, there were a total of 561 respiratory trials and the total number of trials conducted in Canada within the respiratory therapy area significantly increased by 4.49 per year (P=0.004) ( Table 1) . As shown in Figure 1 of asthma trials conducted in Canada has since declined over the past four years, with 10 trials performed in asthma in 2011. In contrast, the number of trials in COPD and respiratory infections have gradually increased over the 10-year period.
Over the 10-year period, 37 trials were designated as phase I, 173 were phase II, 224 were phase III and 124 were phase IV (Figure 3 The value of clinical trials is highlighted in recent reports (6,9) and action plans (10, 11) , published by Rx&D, Canadian Institutes for Health Research and Association of Canadian Academic Healthcare Organizations, focusing on initiatives to assist in improving processes and, as such, attract more clinical trials to Canada. The recommendations include maintaining and continuing to build Canadian health care and research infrastructure and expertise, maintain ethical standards for human subject research but improve efficiency of ethics review, development of a national patient recruitment strategy and patient database, as well as implementing standard operating procedures and training at clinical trial sites countrywide (10, 11) . It is hoped that these initiatives will assist in addressing some of the barriers and issues identified as potential explanations for the decreasing trend in clinical trial research in Canada (6) .
There were several limitations to the present study. First, no formal quality assessments of the trials in the Trialtrove search results were performed. Second, although Trialtrove's clinical trials database is comprehensive, it is important to highlight that trial information is added as it is identified through various sources in the public domain and, therefore, may not include all clinical trials. In addition, the Trialtrove dataset only includes trials for marketed or pipeline drugs and does not include studies in which there is no drug intervention, retrospective studies or meta-analyses (5). Nonmedicinal clinical trials, such as trials investigating alternative strategies for disease management, are, therefore, not included in the dataset and, as such, the total number of trials, particularly those that are non-industrysponsored, may be under-represented. An additional limitation of the present study was that no a priori statistical plan was developed and the statistical analyses were performed on an ad hoc basis. To mitigate any selection bias on the analysis, all available data were modelled using linear regression and the trends in the 10-year study period are reported. Also, it should be noted that no formal comparison among the different types of trials was performed. Although such comparisons would be of great interest, they were beyond the scope of the present study. Despite these limitations, our study focused on the trend of respiratory clinical trials in Canada and will provide an important mechanism for the Canadian respiratory community to monitor its clinical research.
For the first time, our study provides important baseline data and enables future monitoring of the respiratory clinical research activities in Canada. We hope our approach will further assist the Canadian respiratory community to solidify its global leadership role in respiratory research and its mission to improve Canadian patient access to innovative respiratory medicines.
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